Darcy Berry, MS, LCGC

Darcy Berry, MS, LCGC is a native Floridian and a licensed, certified genetic counselor in the Genetics Risk Assessment Clinic (GRAS) at Moffitt Cancer Center. She earned her Bachelor of Science degree at Miami University of Ohio in 2011 with a minor in Neuroscience and a European Culture & Society Concentration. She then completed her Master of Science in Genetic Counseling at the University of South Carolina in 2013. Darcy gained employment at Navicent Health in Macon, Georgia in 2013 and earned her certification from the American Board of Genetic Counseling in 2014. She was elected as co-chair of the Georgia Cancer Genetics Network (GCGN) from 2018 to 2019.  She was the sole clinician at the cancer genetic counseling clinic for nearly five years in Macon, GA before joining the team at Moffitt in the fall of 2018. She was excited to return home to Florida and to work with the brilliant minds at Moffitt and USF to advance the field of genetic counseling and improve the lives of those affected by hereditary cancer.  While at Moffitt, she has enjoyed her role as an Affiliate Assistant Professor at USF’s College of Public Health, teaching hereditary cancer lectures for the genetic counseling students and serving as a rotation supervisor. Darcy was the treasurer of the Florida Association of Genetic Counselors (FLAGC) from the fall of 2018 until the summer of 2024. She earned her Florida Genetic Counseling license in 2021, when licensure for Genetic Counseling was instituted in the state. Darcy is passionate about patient care and optimistic about how genetic testing improves the lives of Moffitt’s patients. 

• Miao R, Blue K, Sommerer K, Shah A, Bottiglieri S, Del Cueto A, Berry DK, Ho TT, Hicks JK, Kim DW. PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience. Cancers (Basel). 2024 Oct.16(20). Pubmedid: 39456541. Pmcid: PMC11505755.
• Berry DK, Gillis N, Padron E, Moore C, Barton LV, Gewandter KR, Haskins CG, Knepper TC. Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance. J Genet Couns. 2024 Aug.33(4):916-926. Pubmedid: 37715966.
• Weatherill CB, Burke SA, Haskins CG, Berry DK, Homer JP, Demeure MJ, Darabi S. Six case reports of NTHL1-associated tumor syndrome further support it as a multi-tumor predisposition syndrome. Clin Genet. 2023 Feb.103(2):231-235. Pubmedid: 36196035.
• Moore C, Berry DK, Gewandter KR. Breaking Down the Barriers of Hereditary Cancer Risk Disclosure in AYA. Pediatrics. 2022 Aug.150(2). Pubmedid: 35859132.
• Zale A, Zierhut H, Dean M, Berry DK, Racobaldo M, Cragun D. Revising the FOCUS framework through a qualitative study assessing self-reported counseling skills of genetic counselors. J Genet Couns. 2022 Aug.31(4):868-886. Pubmedid: 35132718.
• McDonald J, Chuang CY, Hicks JK, Berry DK, Imanirad I, Rishi A, Frakes JM, Hoffe SE, Felder S. FANCD2 Mutation in a Patient With Early Rectal Cancer Receiving Definitive Chemoradiation. Adv Radiat Oncol. 2021 May.6(5):100717. Pubmedid: 34258475. Pmcid: PMC8260782.
• Berry DK, Wang X, Michalski ST, Kang HC, Yang S, Creelan BC, McLeod HL, Hicks JK. Clinical Cohort Analysis of Germline EGFR T790M Demonstrates Penetrance Across Ethnicities and Races, Sexes, and Ages. JCO Precis Oncol. 2020 Mar.4. Pubmedid: 34164592. Pmcid: PMC8216676.